Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research
26 Mai 2023 - 6:00PM
Business Wire
Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage
biotechnology company focused on the development of innovative
drugs for the treatment of cardiovascular emergencies, in
particular stroke, announces today that it will participate in the
European Stroke Organization Conference (ESOC) 2023 on May 24, 25
and 26, 2023 in Munich, Germany.
ESOC is the leading European forum for stroke research and the
preferred platform for the publication of major clinical trial
data.
At this conference, the Company presented three posters on the
clinical development of glenzocimab:
1) Design of the ACTISAVE study (Abstract
N°2314 - Poster n° P0511- session of May 25, 2023) Authors: Y.
Pletan et al. This poster presents the methodology of the ACTISAVE
study and the mapping of its global launch.
2) Sub-analysis of the ACTIMIS study -
Glenzocimab Tolerance in association with antithrombotics (Abstract
N°2314 - Poster n° P0507 - session of May 25, 2023) Authors: A.
Peeters et al. This poster presents the results of a subgroup
analysis of the ACTIMIS study in patients who received
antithrombotic therapy in addition to glenzocimab. This
sub-analysis confirms the very good safety profile of glenzocimab
in these patients.
3) Sub-analysis of the ACTIMIS study -
Patients over 80 years old (Abstract N°618 - e-Poster n° P1018
- session of May 24, 2023) Authors: S. Richard et al. This poster
presents results of a subgroup analysis of the ACTIMIS study in
patients over 80 years of age who received the standard of care
(thrombolysis + thrombectomy). These patients are frequently
excluded from clinical trials because they are at higher risk. The
results of ACTIMIS indicate that glenzocimab does not present
safety issues in these patients and show a marked efficacy trend
towards effectiveness in reducing disability and mortality.
Prior to this event, Acticor Biotech held a Scientific Committee
meeting on Tuesday, May 23, 2023, to discuss the progress and
prospects of the Phase 2/3 clinical trial, ACTISAVE, as well as the
clinical study and registration plans for glenzocimab on the
different continents. In addition, a round table for ACTISAVE
investigators attending ESOC was held on Wednesday, May 24 to
discuss the operational aspects of the trial. Professor Steve
Watson (University of Birmingham) presented the history of the
discovery of GPVI, the target of glenzocimab, and its
antithrombotic properties without the risk of bleeding.
Sophie BINAY, Chief Operating Officer and Chief Scientific
Officer, stated: "The posters presented at this key conference
for stroke research and the holding of our Scientific Advisory
Board and a round table discussion with the participation of
numerous investigators and partners, underline the significant role
played by Acticor Biotech in this ecosystem and the urgent need for
new innovative treatments in stroke. We continue our efforts every
day to develop our drug candidate glenzocimab to address the
important medical challenge of stroke and cardiovascular
emergencies in general.”
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
In May 2022, Acticor Biotech presented positive results from its
Phase 1b/2a study, ACTIMIS, at the ESOC, confirming the safety
profile and showing a reduction in mortality and intracerebral
hemorrhage in the glenzocimab-treated group in patients with
stroke. The efficacy of glenzocimab is now being evaluated in an
international Phase 2/3 study, ACTISAVE, which will include 1,000
patients. In July 2022, Acticor Biotech was granted "PRIME" status
by the European Medicines Agency (EMA) for glenzocimab in the
treatment of stroke. This designation will allow the company to
strengthen its interactions and obtain early dialogues with
regulatory authorities.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation).
Acticor Biotech is listed on Euronext Growth Paris since November
2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230526005204/en/
ACTICOR BIOTECH Gilles AVENARD, MD General Manager and
founder gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD Chief Operating Officer and Scientific
Director Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN / Quentin MASSÉ Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Acticor Biotech (EU:ALACT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024